TB-500 Dosage Guide: Reconstitution, Syringe Units & Research Protocol

TB-500 research dosing guide: loading vs maintenance protocol, reconstitution math for 5mg vials, half-life, BPC-157 comparison, and pre-filled syringe calculator.

TL;DR

• TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein involved in actin regulation and tissue repair
• Promotes healing through actin sequestration, VEGF upregulation, and anti-inflammatory signaling
• Standard research protocols use a loading phase of 5–10 mg/week for 4–6 weeks, followed by a maintenance phase of 2–5 mg/week
• 5mg vials are the most common supply format; half-life is estimated at several days, supporting twice-weekly dosing
• Use the TB-500 Reconstitution Calculator →

⚠️ Disclaimer: This article is written for educational and research purposes only. TB-500 is not FDA-approved for human use and is not classified as a dietary supplement. All information presented here is based on preclinical research and available scientific literature. Nothing in this article constitutes medical advice. Consult a licensed healthcare professional before making any decisions related to peptide research compounds.

Thymosin Beta-4 is one of the most abundant intracellular proteins in virtually all human cells, yet its role in tissue repair and regeneration has only begun to be systematically characterized in research over the past two decades. TB-500 is the synthetic research form of its active region, used in studies exploring wound healing, muscle repair, tendon recovery, and cardiac tissue regeneration. Unlike many peptides that target a single receptor, TB-500 exerts its effects through fundamental cytoskeletal biology — making it one of the more mechanistically interesting compounds in regenerative peptide research.

What distinguishes TB-500 from most other repair-oriented peptides is its unique relationship with actin, the most abundant protein in many cell types. Rather than acting primarily as a growth factor or receptor ligand, TB-500 functions at the level of the cytoskeleton itself. This guide covers the full research picture: mechanism, dosing protocols, reconstitution math, and how TB-500 compares to BPC-157 for tissue repair research.

What Is TB-500?

TB-500 is a synthetic peptide corresponding to the actin-binding domain of Thymosin Beta-4 (Tβ4) — specifically the amino acid sequence Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser. At 43 amino acids, it is considerably larger than many peptides commonly used in research (BPC-157, for example, is 15 amino acids).

The naturally occurring Thymosin Beta-4 is found in virtually every nucleated cell in the body and plays essential roles in cell survival, migration, proliferation, and differentiation. It was first characterized in thymic tissue, hence the "thymosin" designation, but its expression and function are broadly distributed throughout the body. The synthetic TB-500 fragment retains the biological activity of the full-length protein with improved stability and water solubility for research applications.

TB-500 is particularly relevant in contexts involving tissue damage and repair because Thymosin Beta-4 expression is acutely upregulated in response to injury. Cardiac tissue studies have shown that Tβ4 levels increase dramatically following myocardial infarction, suggesting it plays a physiological role in the body's natural repair response. TB-500 research effectively studies what happens when this endogenous response is amplified or supplemented exogenously.

Mechanism of Action

TB-500's mechanism is multifaceted, with three primary pathways driving its biological effects:

Actin Sequestration and Cytoskeletal Modulation. The core molecular function of Thymosin Beta-4 is binding to G-actin (globular, monomeric actin) and preventing its polymerization into F-actin (filamentous actin). This actin-buffering activity regulates the dynamic assembly of the cytoskeleton, which in turn controls cell shape, motility, and division. In the context of tissue repair, this translates to enhanced cell migration — cells at the edges of wounds can more rapidly reorganize their cytoskeletons and migrate into the injury zone to initiate repair. TB-500 essentially lubricates this process by increasing the pool of available G-actin for rapid cytoskeletal remodeling.

VEGF Upregulation and Angiogenesis. Like BPC-157, TB-500 has been shown in multiple studies to upregulate vascular endothelial growth factor (VEGF) expression, promoting the formation of new blood vessels (angiogenesis) in damaged tissue. This is a critical step in tissue repair, as adequate vascular supply delivers oxygen, nutrients, and immune cells to the healing area. In cardiac repair models particularly, TB-500's ability to promote angiogenesis in ischemic tissue has attracted significant research interest.

Anti-inflammatory Signaling. TB-500 has demonstrated significant anti-inflammatory activity in animal models, reducing the expression of pro-inflammatory cytokines and attenuating the inflammatory cascade that can prolong tissue damage and impair healing. This anti-inflammatory effect is thought to be mediated partly through its interactions with macrophage and neutrophil function, and through the indirect effects of cytoskeletal modulation on immune cell behavior.

Research Dosing Patterns

TB-500 research protocols are generally structured in two distinct phases that reflect the compound's proposed mechanism — an initial period of intensive administration to saturate tissue receptors and establish effect, followed by a lower-maintenance phase:

Loading Phase. The standard loading protocol in research studies runs 4–6 weeks with doses of 5–10 mg per week, typically split into two administrations of 2.5–5 mg each. The rationale for split dosing during loading is the compound's multi-day half-life — twice-weekly injections maintain more consistent plasma and tissue levels than single weekly injections.

• Low-end loading: 5 mg/week (2 × 2.5 mg)
• High-end loading: 10 mg/week (2 × 5 mg)

Maintenance Phase. Following the loading period, research protocols transition to a maintenance dose of 2–5 mg per week, again typically split across two administrations. Some protocols use a simplified once-weekly maintenance dose, particularly in longer-term chronic studies. Maintenance phases in the literature range from 4 weeks to several months depending on the research question.

It is worth noting that TB-500 doses are substantially larger than those of shorter peptides like BPC-157 or Ipamorelin. This reflects the larger molecular weight (43 amino acids vs. 15 amino acids for BPC-157) and the different receptor engagement mechanics involved. Higher absolute doses translate to more BAC water required and larger injection volumes, which is an important practical consideration when designing protocols.

Reconstitution Math

TB-500 is most commonly supplied in 5mg vials. The following table provides concentration and volume reference data for three common reconstitution ratios:

*Doses marked with an asterisk exceed the volume of a single standard U-100 insulin syringe (1 mL / 100 units). For these doses, use a standard 1 mL or 3 mL syringe with graduated markings rather than an insulin syringe, or split into multiple injection sites.

All unit values assume a standard U-100 insulin syringe (100 units = 1 mL) where applicable.

For the typical 2.5 mg loading dose (half of a 5mg/week loading protocol), the 1 mL reconstitution (5,000 mcg/mL) is practical because a 2.5 mg dose corresponds to exactly 0.5 mL — a clean, easy-to-measure volume. The 2 mL reconstitution (2,500 mcg/mL) is also widely used, resulting in a 1 mL draw for a 2.5 mg dose, though this hits the maximum volume of an insulin syringe and may be better handled with a 1 mL standard syringe.

Calculate your TB-500 dose → Reconstitution Calculator | Half-Life Calculator

Use the TB-500 Reconstitution Calculator → to verify your syringe volumes for any dose and reconstitution ratio.

Subcutaneous Administration Guide

TB-500 is primarily administered via subcutaneous injection in research settings. Given the relatively large injection volumes involved compared to shorter peptides, technique and site selection are important considerations.

Preferred injection sites for subcutaneous TB-500 administration include:

1. Abdominal subcutaneous tissue — the most common site, offering a large surface area with abundant subcutaneous fat and easy access. Inject at least 2 inches from the navel.
2. Upper thigh — the outer portion of the thigh provides another accessible subcutaneous site with good tissue volume.
3. Flank / lateral abdomen — alternatively, the love handle area offers substantial subcutaneous tissue depth.

Rotate injection sites systematically across administrations to prevent lipodystrophy (localized changes in subcutaneous fat from repeated injection) and minimize local irritation. For large volumes (>1 mL), injecting slowly over 20–30 seconds minimizes discomfort and reduces the risk of local tissue reaction.

Some research protocols have used intraperitoneal (IP) injection in rodent models, particularly for systemic dosing studies. For subcutaneous studies in larger animals or human-equivalent research, subcutaneous delivery is standard. Intramuscular administration is less common but has been used in some musculoskeletal repair studies.

TB-500 vs BPC-157: Comparison Table

TB-500 and BPC-157 are the two most widely researched peptides in the tissue repair space, and they are frequently discussed together. While they share some overlapping mechanisms (both upregulate VEGF, both have anti-inflammatory properties), they are structurally and mechanistically quite distinct:

A key practical difference is that TB-500's much longer half-life supports less frequent dosing — twice weekly is standard during loading — whereas BPC-157's short 4-hour half-life typically necessitates twice-daily administration for protocols seeking sustained systemic exposure. For localized musculoskeletal research, BPC-157 may be preferred due to the established practice of site-specific injection near the target structure. For more systemic repair applications — particularly cardiac and widespread wound healing models — TB-500 may offer advantages through its actin-based mechanism and longer half-life.

Storage & Shelf Life

Lyophilized (unreconstituted) TB-500 powder should be stored at -20°C (freezer) for long-term stability, typically up to 24 months. Short-term storage at 4°C (refrigerator) is acceptable for vials that will be reconstituted and used within a few weeks. Always protect from light and moisture.

Reconstituted TB-500 solution (in bacteriostatic water) should be stored at 4°C (refrigerator) and used within 4–6 weeks of reconstitution. The benzyl alcohol preservative in bacteriostatic water extends usable life significantly compared to sterile water reconstitution — see the bacteriostatic water guide for a full explanation of why BAC water is preferred over sterile water for multi-use vials. Do not freeze the reconstituted solution. Label each vial with the reconstitution date and calculated concentration.

Because TB-500 doses are large and vial consumption is therefore relatively rapid (a 5mg loading-phase protocol exhausts a 5mg vial in two injections at 2.5mg each), storage duration for reconstituted solutions may be less of a concern than with lower-dose compounds where a single vial may last several weeks. Even so, careful labeling and date-tracking remain important practices for maintaining protocol integrity.

Conclusion

TB-500 is a mechanistically unique peptide that works at the level of cellular cytoskeletal biology, distinguishing it from most other repair-focused compounds. Its actin-buffering mechanism, combined with VEGF upregulation and anti-inflammatory activity, gives it a broad tissue repair profile that has been demonstrated across multiple animal model systems. The structured loading-then-maintenance dosing protocol used in most TB-500 research reflects the compound's longer half-life and the theory that initial tissue saturation is important for establishing the full biological response.

For researchers choosing between TB-500 and BPC-157, the compounds are more complementary than competitive — their distinct mechanisms suggest that combination protocols may address a broader set of repair pathways than either compound alone. For guidance on running multi-peptide protocols, see the peptide stack calculator guide. Use the reconstitution calculator to set up your vials correctly, and ensure your protocol design accounts for the relatively large injection volumes that TB-500's dose range requires.

Frequently Asked Questions About TB-500

Q: What is TB-500 used for in research? A: TB-500 is primarily studied for its tissue repair and regenerative properties. Research in animal models has examined its effects on wound healing, muscle and tendon recovery, cardiac tissue repair following ischemia, and anti-inflammatory responses. It is particularly notable for cardiac repair research because Thymosin Beta-4 expression increases dramatically following myocardial infarction, suggesting an endogenous repair role that TB-500 can amplify.

Q: How does TB-500 differ from BPC-157? A: TB-500 (43 amino acids) works primarily through actin sequestration and cytoskeletal modulation — enhancing cell migration into injury sites — while BPC-157 (15 amino acids) acts mainly through nitric oxide system modulation and direct fibroblast stimulation. TB-500 has a multi-day half-life that supports twice-weekly dosing, whereas BPC-157's ~4-hour half-life typically requires twice-daily administration. BPC-157 is more established for localized tendon/ligament and gut research, while TB-500 is better studied for systemic and cardiac repair. Many researchers consider them complementary.

Q: What is the typical TB-500 research dose? A: Most research protocols use a two-phase approach: a loading phase of 5–10 mg per week (typically split into two injections of 2.5–5 mg) for 4–6 weeks, followed by a maintenance phase of 2–5 mg per week. The 5 mg/week loading dose (2 × 2.5 mg) is the most commonly referenced starting point. These relatively large doses reflect TB-500's molecular size — at 43 amino acids, it requires substantially more mass to achieve comparable molar concentrations compared to shorter peptides like BPC-157 or Ipamorelin.

Q: How long does it take for TB-500 to work? A: In animal model studies, early signs of tissue repair activity are typically observed within the first 1–2 weeks of the loading phase. However, the full structural remodeling benefits in tendon, muscle, and cardiac models generally develop over 4–8 weeks of consistent administration. The loading-then-maintenance protocol structure reflects the theory that initial tissue saturation is important for establishing the full biological response before transitioning to lower maintenance doses.

Q: How do you reconstitute TB-500? A: TB-500 is supplied as a lyophilized powder, most commonly in 5 mg vials. Adding 1.0 mL of bacteriostatic water creates a 5,000 mcg/mL concentration — for a 2.5 mg loading dose, this gives a clean 0.5 mL draw. A 2.0 mL reconstitution (2,500 mcg/mL) is also common but produces a 1 mL draw for the 2.5 mg dose, which hits the maximum volume of a U-100 insulin syringe. For higher doses (5 mg per injection), a standard 1 mL or 3 mL syringe is recommended rather than an insulin syringe due to the larger volumes involved.

This content is provided for educational and research informational purposes only. TB-500 is not approved for human therapeutic use by the FDA or most regulatory authorities. This article does not constitute medical advice, diagnosis, or treatment recommendations. Researchers should comply with all applicable institutional and legal guidelines.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions